At the end of April, Biogen reported first quarter 2017 financial results, including worldwide revenues of $47 million for Spinraza, a drug approved by the FDA in December 2016 for treatment of spinal muscular atrophy (SMA).
“I am very pleased with the results of the first quarter. We saw continued stability in our MS business, executed a strong launch of Spinraza, grew market share for our biosimilars business across Europe, and reinforced the intellectual property for Tecfidera,” said Chief Executive Officer Michel Vounatsos. “Furthermore, we continued to build our neurology pipeline with the anticipated addition of our new Phase 2-ready anti-tau antibody.”
“We are encouraged by the progress we made launching Spinraza in the U.S., and, following the positive CHMP opinion, we are ramping up pre-launch activities in Europe. The value this therapy provides to patients is compelling, and we are working to accelerate patient access globally,” Vounatsos continued. “Overall, I believe we’re building positive momentum at the company, and I look forward to leading Biogen into a new and exciting era.”
Biogen earlier announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion recommending the granting of a marketing authorization in the European Union for Spinraza. The CHMP reviewed Spinraza under an accelerated assessment procedure, which is a regulatory mechanism to facilitate earlier access to patients for medicines that fulfill unmet medical needs. Spinraza is the first treatment for spinal muscular atrophy to be recommended by the CHMP for approval in the EU. (Source: Biogen Website)
To read the press release visit: http://media.biogen.com/press-release/investor-relations/biogen-reports-first-quarter-2017-revenues-28-billion